Placebo group | Cyclophosphamide group | |||||
---|---|---|---|---|---|---|
Number of subjects | Absolute decline in FVC % predicted, mean (SD) | p Value | Number of subjects | Absolute decline in FVC % predicted, mean (SD) | p Value | |
Visual maximum fibrosis score | ||||||
0–25 % | 19 | 0.1 (9.0) | 0.019 | 13 | −3.4 (6.3) | 0.04 |
26–100 % | 29 | −6.2 (8.3) | 30 | 1.2 (6.6) | ||
Goh and Wells criteria, unadjusted stratification | ||||||
<20 % | 22 | −1.6 (10.2) | 0.15 | 15 | −1.0 (6.7) | 0.49 |
>20 % | 25 | −5.5 (8.0) | 30 | 0.6 (7.7) | ||
Goh and Wells criteria with indeterminate results on HRCT (10–30 %), adjusted stratification | ||||||
Minimal disease | 8 | 2.2 (9.8) | 0.08 | 12 | −1.1 (4.3) | 0.47 |
Extensive disease | 39 | −4.9 (8.7) | 32 | 0.3 (8.2) | ||
QILD WL | ||||||
<20 % | 10 | 0.3 (6.8) | 0.07 | 5 | −7.9 (9.7) | 0.12 |
>20 % | 37 | −4.9 (9.5) | 38 | 0.8 (5.7) | ||
QILD ZM | ||||||
<25 % | 2 | 5.0 (7.5) | 0.32 | 2 | −12.3 (1.5) | 0.001 |
>25 % | 45 | −4.1 (9.1) | 41 | 0.4 (6.4) | ||
QLF WL | ||||||
<20 % | 42 | −3.0 (9.1) | 0.16 | 39 | −0.4 (6.7) | 0.70 |
>20 % | 5 | −9.8 (8.7) | 4 | 1.4 (8.2) | ||
QLF ZM | ||||||
<25 % | 27 | −1.4 (10.1) | 0.03 | 24 | −1.2 (7.2) | 0.26 |
>25 % | 20 | −6.9 (6.8) | 19 | 1.1 (6.2) |